Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 158


Progression of Liver Fibrosis in HIV/HCV Co-Infection: A Comparison between Non-Invasive Assessment Methods and Liver Biopsy.

Schmid P, Bregenzer A, Huber M, Rauch A, Jochum W, Müllhaupt B, Vernazza P, Opravil M, Weber R; Swiss HIV Cohort Study.

PLoS One. 2015 Sep 29;10(9):e0138838. doi: 10.1371/journal.pone.0138838. eCollection 2015.


Effects of once-daily darunavir/ritonavir versus lopinavir/ritonavir on metabolic parameters in treatment-naive HIV-1-infected patients at week 96: ARTEMIS.

Arathoon E, Schneider S, Baraldi E, Lim PL, Opravil M, Van De Casteele T, Lavreys L.

Int J STD AIDS. 2013 Jan;24(1):12-7. doi: 10.1258/ijsa.2012.012120. Epub 2013 May 6.


Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid.

Cusini A, Vernazza PL, Yerly S, Decosterd LA, Ledergerber B, Fux CA, Rohrbach J, Widmer N, Hirschel B, Gaudenz R, Cavassini M, Klimkait T, Zenger F, Gutmann C, Opravil M, Günthard HF; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2013 Jan 1;62(1):28-35. doi: 10.1097/QAI.0b013e318274e2b0. Erratum in: J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e170-1.


The dose-response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCV.

Opravil M, Rodriguez-Torres M, Rockstroh J, Snoeck E, Chung RT, Tietz A, Torriani FJ.

HIV Clin Trials. 2012 Jan-Feb;13(1):33-45. doi: 10.1310/hct1301-033.


Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial.

Soriano V, Arastéh K, Migrone H, Lutz T, Opravil M, Andrade-Villanueva J, Antunes F, Di Perri G, Podzamczer D, Taylor S, Domingo P, Gellermann H, de Rossi L; ARTEN investigators.

Antivir Ther. 2011;16(3):339-48. doi: 10.3851/IMP1745.


Efficacy, tolerability and risk factors for virological failure of darunavir-based therapy for treatment-experienced HIV-infected patients: the Swiss HIV Cohort Study.

Young J, Scherrer AU, Günthard HF, Opravil M, Yerly S, Böni J, Rickenbach M, Fux CA, Cavassini M, Bernasconi E, Vernazza P, Hirschel B, Battegay M, Bucher HC; Swiss HIV Cohort Study.

HIV Med. 2011 May;12(5):299-307. doi: 10.1111/j.1468-1293.2010.00885.x. Epub 2010 Oct 18.


Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort study.

Osih RB, Taffé P, Rickenbach M, Gayet-Ageron A, Elzi L, Fux C, Opravil M, Bernasconi E, Schmid P, Günthard HF, Cavassini M; Swiss HIV Cohort Study.

AIDS Res Hum Retroviruses. 2010 Nov;26(11):1239-46. doi: 10.1089/aid.2010.0070. Epub 2010 Oct 7.


Diffusion-weighted MR imaging of intramedullary spinal cord abscess.

Dörflinger-Hejlek E, Kirsch EC, Reiter H, Opravil M, Kaim AH.

AJNR Am J Neuroradiol. 2010 Oct;31(9):1651-2. doi: 10.3174/ajnr.A1912. Epub 2009 Dec 17.


Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007.

Ballif M, Ledergerber B, Battegay M, Cavassini M, Bernasconi E, Schmid P, Hirschel B, Furrer H, Rickenbach M, Opravil M, Weber R; Swiss HIV Cohort Study.

PLoS One. 2009 Dec 14;4(12):e8275. doi: 10.1371/journal.pone.0008275.


Implementation of raltegravir in routine clinical practice: selection criteria for choosing this drug, virologic response rates, and characteristics of failures.

Scherrer AU, von Wyl V, Fux CA, Opravil M, Bucher HC, Fayet A, Decosterd LA, Hirschel B, Khanlari B, Yerly S, Klimkait T, Furrer H, Ledergerber B, Günthard HF; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):464-71. doi: 10.1097/QAI.0b013e3181bca4ec.


Prior therapy influences the efficacy of lamivudine monotherapy in patients with lamivudine-resistant HIV-1 infection.

Opravil M, Klimkait T, Louvel S, Wolf E, Battegay M, Fux CA, Bernasconi E, Vogel M, Speck R, Weber R; Swiss HIV Cohort Study.

J Acquir Immune Defic Syndr. 2010 May 1;54(1):51-8. doi: 10.1097/QAI.0b013e3181bef889.


Cost-effectiveness of raltegravir in antiretroviral treatment-experienced HIV-1-infected patients in Switzerland.

Elbasha EE, Szucs T, Chaudhary MA, Kumar RN, Roediger A, Cook JR, Opravil M.

HIV Clin Trials. 2009 Jul-Aug;10(4):233-53. doi: 10.1310/hct1004-233.


Tenofovir use is associated with an increase in serum alkaline phosphatase in the Swiss HIV Cohort Study.

Fux CA, Rauch A, Simcock M, Bucher HC, Hirschel B, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Elzi L, Furrer H; Swiss HIV Cohort Study.

Antivir Ther. 2008;13(8):1077-82.


Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study.

Rauch A, Nolan D, Thurnheer C, Fux CA, Cavassini M, Chave JP, Opravil M, Phillips E, Mallal S, Furrer H; Swiss HIV Cohort Study.

Antivir Ther. 2008;13(8):1019-28.


Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era.

Opravil M, Sereni D.

AIDS. 2008 Sep;22 Suppl 3:S35-40. doi: 10.1097/01.aids.0000327514.60879.47.


Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.

Pozniak A, Opravil M, Beatty G, Hill A, de Béthune MP, Lefebvre E.

AIDS Res Hum Retroviruses. 2008 Oct;24(10):1275-80. doi: 10.1089/aid.2007.0275.


CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy.

Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR; Swiss HIV Cohort Study.

Clin Infect Dis. 2008 Oct 15;47(8):1093-101. doi: 10.1086/592113. Erratum in: Clin Infect Dis. 2009 May 15;48(10):1491.


Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.

Landovitz RJ, Angel JB, Hoffmann C, Horst H, Opravil M, Long J, Greaves W, Fätkenheuer G.

J Infect Dis. 2008 Oct 15;198(8):1113-22. doi: 10.1086/592052.


Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the Swiss HIV Cohort Study.

Fux CA, Simcock M, Wolbers M, Bucher HC, Hirschel B, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Elzi L, Furrer H; Swiss HIV Cohort Study.

Antivir Ther. 2007;12(8):1165-73.


Adverse events to antiretrovirals in the Swiss HIV Cohort Study: effect on mortality and treatment modification.

Keiser O, Fellay J, Opravil M, Hirsch HH, Hirschel B, Bernasconi E, Vernazza PL, Rickenbach M, Telenti A, Furrer H; Swiss HIV Cohort Study.

Antivir Ther. 2007;12(8):1157-64.


Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000-2006.

Nguyen A, Calmy A, Schiffer V, Bernasconi E, Battegay M, Opravil M, Evison JM, Tarr PE, Schmid P, Perneger T, Hirschel B; Swiss HIV Cohort Study.

HIV Med. 2008 Mar;9(3):142-50. doi: 10.1111/j.1468-1293.2007.00537.x. Epub 2008 Jan 22.


Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection.

Opravil M, Sasadeusz J, Cooper DA, Rockstroh JK, Clumeck N, Clotet B, Montaner J, Torriani FJ, Depamphilis J, Dieterich DT.

J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):36-49.


Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study.

Wolbers M, Opravil M, von Wyl V, Hirschel B, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Battegay M, Yerly S, Günthard H, Bucher HC; Swiss HIV Cohort Study.

AIDS. 2007 Oct 18;21(16):2201-7.


Is depression a risk factor for heart complaints? Longitudinal aspects in the Zurich study.

Eich D, Neuhaus C, Gamma A, Angst J, Rössler W, Ajdacic-Gross V, Opravil M.

Eur Arch Psychiatry Clin Neurosci. 2007 Oct;257(7):396-401.


Combined tipranavir and enfuvirtide use associated with higher plasma tipranavir concentrations but not with increased hepatotoxicity: sub-analysis from RESIST.

Raffi F, Battegay M, Rusconi S, Opravil M, Blick G, Steigbigel RT, Kraft M, Neubacher D, Sabo JP.

AIDS. 2007 Sep 12;21(14):1977-80. Erratum in: AIDS. 2008 Aug 20;22(13):i.


Acute interstitial nephritis of HIV-positive patients under atazanavir and tenofovir therapy in a retrospective analysis of kidney biopsies.

Schmid S, Opravil M, Moddel M, Huber M, Pfammatter R, Keusch G, Ambuhl P, Wuthrich RP, Moch H, Varga Z.

Virchows Arch. 2007 Jun;450(6):665-70. Epub 2007 Apr 27.


Treatment initiation with zidovudine-containing potent antiretroviral therapy impairs CD4 cell count recovery but not clinical efficacy.

Huttner AC, Kaufmann GR, Battegay M, Weber R, Opravil M.

AIDS. 2007 May 11;21(8):939-46.


Persistence of lamivudine-sensitive HIV-1 quasispecies in the presence of lamivudine in vitro and in vivo.

Allers K, Knoepfel SA, Rauch P, Walter H, Opravil M, Fischer M, Günthard HF, Metzner KJ.

J Acquir Immune Defic Syndr. 2007 Apr 1;44(4):377-85.


Equal amounts of intracellular and virion-enclosed hepatitis C virus RNA are associated with peripheral-blood mononuclear cells in vivo.

Kaiser P, Niederost B, Joos B, von Wyl V, Opravil M, Weber R, Gunthard HF, Fischer M.

J Infect Dis. 2006 Dec 15;194(12):1713-23. Epub 2006 Nov 13.


HIV replication elicits little cytopathic effects in vivo: analysis of surrogate markers for virus production, cytotoxic T cell response and infected cell death.

Funk GA, Oxenius A, Fischer M, Opravil M, Joos B, Flepp M, Weber R, Günthard HF, Bonhoeffer S.

J Med Virol. 2006 Sep;78(9):1141-6.


Optimized virus disruption improves detection of HIV-1 p24 in particles and uncovers a p24 reactivity in patients with undetectable HIV-1 RNA under long-term HAART.

Schüpbach J, Tomasik Z, Knuchel M, Opravil M, Günthard HF, Nadal D, Böni J; Swiss HIV Cohort Study; Swiss HIV Mother + Child Cohort Study.

J Med Virol. 2006 Aug;78(8):1003-10.


Discontinuation of maintenance therapy against toxoplasma encephalitis in AIDS patients with sustained response to anti-retroviral therapy.

Bertschy S, Opravil M, Cavassini M, Bernasconi E, Schiffer V, Schmid P, Flepp M, Chave JP, Christen A, Furrer H; Swiss HIV Cohort Study.

Clin Microbiol Infect. 2006 Jul;12(7):666-71.


Eligibility for and outcome of hepatitis C treatment of HIV-coinfected individuals in clinical practice: the Swiss HIV cohort study.

Zinkernagel AS, von Wyl V, Ledergerber B, Rickenbach M, Furrer H, Battegay M, Hirschel B, Tarr PE, Opravil M, Bernasconi E, Schmid P, Weber R; Swiss HIV Cohort Study.

Antivir Ther. 2006;11(2):131-42.


[Infectious spondylitis].

Huttner B, Opravil M.

Z Rheumatol. 2006 Feb;65(1):7-11. Review. German.


Characteristics, determinants, and clinical relevance of CD4 T cell recovery to <500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy.

Kaufmann GR, Furrer H, Ledergerber B, Perrin L, Opravil M, Vernazza P, Cavassini M, Bernasconi E, Rickenbach M, Hirschel B, Battegay M; Swiss HIV Cohort Study.

Clin Infect Dis. 2005 Aug 1;41(3):361-72. Epub 2005 Jun 24.


Long-term survival and interruption of HAART in HIV-related pulmonary hypertension.

Zinkernagel AS, von Overbeck J, Opravil M, Jenni R, Speich R, Mueller NJ.

Eur J Clin Microbiol Infect Dis. 2005 Feb;24(2):153-5.


Updated European recommendations for the clinical use of HIV drug resistance testing.

Vandamme AM, Sönnerborg A, Ait-Khaled M, Albert J, Asjo B, Bacheler L, Banhegyi D, Boucher C, Brun-Vézinet F, Camacho R, Clevenbergh P, Clumeck N, Dedes N, De Luca A, Doerr HW, Faudon JL, Gatti G, Gerstoft J, Hall WW, Hatzakis A, Hellmann N, Horban A, Lundgren JD, Kempf D, Miller M, Miller V, Myers TW, Nielsen C, Opravil M, Palmisano L, Perno CF, Phillips A, Pillay D, Pumarola T, Ruiz L, Salminen M, Schapiro J, Schmidt B, Schmit JC, Schuurman R, Shulse E, Soriano V, Staszewski S, Vella S, Youle M, Ziermann R, Perrin L.

Antivir Ther. 2004 Dec;9(6):829-48.


Predictive value of adherence in patients starting highly active antiretroviral treatment for HIV infection.

Wagels T, Amiet R, Battegay M, Guex AC, Opravil M, Vernazza PL; Swiss HIV Cohort Study Group.

Swiss Med Wkly. 2004 Nov 13;134(45-46):678-80.


Alveolar echinococcosis of the liver in an adult with human immunodeficiency virus type-1 infection.

Zingg W, Renner-Schneiter EC, Pauli-Magnus C, Renner EL, van Overbeck J, Schläpfer E, Weber M, Weber R, Opravil M, Gottstein B, Speck RF; Swiss HIV Cohort Study.

Infection. 2004 Oct;32(5):299-302.


Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine.

Opravil M, Baumann D, Chave JP, Furrer H, Calmy A, Bernasconi E, Blasko M, Vernazza P, Ledergerber B, Perrin L; Swiss HIV Cohort Study.

AIDS. 2004 Nov 5;18(16):2213-5. No abstract available.


Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study.

Zellweger C, Opravil M, Bernasconi E, Cavassini M, Bucher HC, Schiffer V, Wagels T, Flepp M, Rickenbach M, Furrer H; Swiss HIV Cohort Study.

AIDS. 2004 Oct 21;18(15):2047-53.


CCTTT-repeat polymorphism of the inducible nitric oxide synthase is not associated with HIV pathogenesis.

Hersberger M, Bonhoeffer S, Rampini SK, Opravil M, Marti-Jaun J, Telenti A, Hänseler E, Ledergerber B, Speck RF; Swiss HIV Cohort Study.

Clin Exp Immunol. 2004 Sep;137(3):566-9.


Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension.

Sitbon O, Gressin V, Speich R, Macdonald PS, Opravil M, Cooper DA, Fourme T, Humbert M, Delfraissy JF, Simonneau G.

Am J Respir Crit Care Med. 2004 Dec 1;170(11):1212-7. Epub 2004 Aug 18.


Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy.

Zuber JP, Calmy A, Evison JM, Hasse B, Schiffer V, Wagels T, Nuesch R, Magenta L, Ledergerber B, Jenni R, Speich R, Opravil M; Swiss HIV Cohort Study Group.

Clin Infect Dis. 2004 Apr 15;38(8):1178-85. Epub 2004 Apr 1.


Effect of individual cognitive behaviour intervention on adherence to antiretroviral therapy: prospective randomized trial.

Weber R, Christen L, Christen S, Tschopp S, Znoj H, Schneider C, Schmitt J, Opravil M, Günthard HF, Ledergerber B; Swiss HIV Cohort Study.

Antivir Ther. 2004 Feb;9(1):85-95.


HIV-specific cellular immune response is inversely correlated with disease progression as defined by decline of CD4+ T cells in relation to HIV RNA load.

Oxenius A, Price DA, Hersberger M, Schlaepfer E, Weber R, Weber M, Kundig TM, Böni J, Joller H, Phillips RE, Flepp M, Opravil M, Speck RF; Swiss HIV Cohort Study.

J Infect Dis. 2004 Apr 1;189(7):1199-208. Epub 2004 Mar 17.


Attenuated and nonproductive viral transcription in the lymphatic tissue of HIV-1-infected patients receiving potent antiretroviral therapy.

Fischer M, Joos B, Wong JK, Ott P, Opravil M, Hirschel B, Weber R, Günthard HF; Swiss HIV Cohort Study.

J Infect Dis. 2004 Jan 15;189(2):273-85. Epub 2004 Jan 7.


Impact of genotypic resistance testing on selection of salvage regimen in clinical practice.

Haupts S, Ledergerber B, Böni J, Schüpbach J, Kronenberg A, Opravil M, Flepp M, Speck RF, Grube C, Rentsch K, Weber R, Günthard HF; Swiss HIV Cohort Study.

Antivir Ther. 2003 Oct;8(5):443-54.


CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.

Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M; Swiss HIV Cohort Study Group.

Arch Intern Med. 2003 Oct 13;163(18):2187-95.


Supplemental Content

Loading ...
Support Center